NO2017011I1 - Buprenorfin - Google Patents

Buprenorfin

Info

Publication number
NO2017011I1
NO2017011I1 NO2017011C NO2017011C NO2017011I1 NO 2017011 I1 NO2017011 I1 NO 2017011I1 NO 2017011 C NO2017011 C NO 2017011C NO 2017011 C NO2017011 C NO 2017011C NO 2017011 I1 NO2017011 I1 NO 2017011I1
Authority
NO
Norway
Prior art keywords
buprenorphine
provides
over
days
composition comprises
Prior art date
Application number
NO2017011C
Other languages
English (en)
Original Assignee
Mundipharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26715643&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2017011(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mundipharma As filed Critical Mundipharma As
Publication of NO2017011I1 publication Critical patent/NO2017011I1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Saccharide Compounds (AREA)
NO2017011C 1997-02-24 2017-04-04 Buprenorfin NO2017011I1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3891997P 1997-02-24 1997-02-24
US08/939,068 US5968547A (en) 1997-02-24 1997-09-29 Method of providing sustained analgesia with buprenorphine
PCT/US1998/003584 WO1998036728A2 (en) 1997-02-24 1998-02-24 Sustained analgesia achieved with buprenorphine

Publications (1)

Publication Number Publication Date
NO2017011I1 true NO2017011I1 (no) 2017-04-04

Family

ID=26715643

Family Applications (11)

Application Number Title Priority Date Filing Date
NO994087A NO322515B1 (no) 1997-02-24 1999-08-24 Anvendelse av buprenorfin i fremstillingen av et transdermalt avleveringssystem for behandling av smerte hos en human pasient
NO20064395A NO329734B1 (no) 1997-02-24 2006-09-28 Anvendelse av buprenorfin i fremstilling av et medikament
NO20074292A NO329838B1 (no) 1997-02-24 2007-08-22 Anvendelse av et polymermatrikslag som inkluderer buprenorfin eller et farmasøytisk akseptabelt salt derav
NO20101190A NO332248B1 (no) 1997-02-24 2010-08-23 Transdermal avleveringsinnretning og anvendelse av buprenorfin i fremstillingen av et medikament.
NO20111441A NO333374B1 (no) 1997-02-24 2011-10-24 Transdermal avleveringsinnretning omfattende buprenorfin
NO20120563A NO333139B1 (no) 1997-02-24 2012-05-14 Transdermal avleveringsinnretning som omfatter buprenorfin og anvendelse av buprenorfin i fremstillingen av et medikament for behandling av smerte
NO20130298A NO334290B1 (no) 1997-02-24 2013-02-26 Transdermal avleveringsinnretning inneholdende buprenorfin for anvendelse ved behandling av smerte samt fremgangsmåte for fremstilling derav
NO20131533A NO337094B1 (no) 1997-02-24 2013-11-18 Anvendelse av buprenorfin i fremstillingen av et transdermalt avleveringssystem for behandling av smerte hos en human pasient
NO20151450A NO340067B1 (no) 1997-02-24 2015-10-26 Buprenorfin transdermal avleveringsanordning for anvendelse ved smertebehandling av en human pasient
NO2016013C NO2016013I1 (no) 1997-02-24 2016-07-18 Buprenorfin; 21-syklopropyl-7µ-[(S)-1-hydroksy-1,2,3-trimetylpropyl]-6,14-endoetano-6,7,8,14-tetrahydrooripavin
NO2017011C NO2017011I1 (no) 1997-02-24 2017-04-04 Buprenorfin

Family Applications Before (10)

Application Number Title Priority Date Filing Date
NO994087A NO322515B1 (no) 1997-02-24 1999-08-24 Anvendelse av buprenorfin i fremstillingen av et transdermalt avleveringssystem for behandling av smerte hos en human pasient
NO20064395A NO329734B1 (no) 1997-02-24 2006-09-28 Anvendelse av buprenorfin i fremstilling av et medikament
NO20074292A NO329838B1 (no) 1997-02-24 2007-08-22 Anvendelse av et polymermatrikslag som inkluderer buprenorfin eller et farmasøytisk akseptabelt salt derav
NO20101190A NO332248B1 (no) 1997-02-24 2010-08-23 Transdermal avleveringsinnretning og anvendelse av buprenorfin i fremstillingen av et medikament.
NO20111441A NO333374B1 (no) 1997-02-24 2011-10-24 Transdermal avleveringsinnretning omfattende buprenorfin
NO20120563A NO333139B1 (no) 1997-02-24 2012-05-14 Transdermal avleveringsinnretning som omfatter buprenorfin og anvendelse av buprenorfin i fremstillingen av et medikament for behandling av smerte
NO20130298A NO334290B1 (no) 1997-02-24 2013-02-26 Transdermal avleveringsinnretning inneholdende buprenorfin for anvendelse ved behandling av smerte samt fremgangsmåte for fremstilling derav
NO20131533A NO337094B1 (no) 1997-02-24 2013-11-18 Anvendelse av buprenorfin i fremstillingen av et transdermalt avleveringssystem for behandling av smerte hos en human pasient
NO20151450A NO340067B1 (no) 1997-02-24 2015-10-26 Buprenorfin transdermal avleveringsanordning for anvendelse ved smertebehandling av en human pasient
NO2016013C NO2016013I1 (no) 1997-02-24 2016-07-18 Buprenorfin; 21-syklopropyl-7µ-[(S)-1-hydroksy-1,2,3-trimetylpropyl]-6,14-endoetano-6,7,8,14-tetrahydrooripavin

Country Status (22)

Country Link
US (15) US5968547A (no)
EP (9) EP1570823B1 (no)
JP (1) JP2000511936A (no)
KR (1) KR100703101B1 (no)
CN (2) CN1252705A (no)
AT (3) ATE336212T1 (no)
AU (2) AU2004218685B2 (no)
BR (1) BR9815439A (no)
CA (1) CA2276170C (no)
CZ (2) CZ299414B6 (no)
DE (2) DE69835584T2 (no)
DK (4) DK1731152T3 (no)
ES (4) ES2387752T3 (no)
HK (3) HK1096847A1 (no)
HU (3) HU230374B1 (no)
IL (4) IL131561A0 (no)
NO (11) NO322515B1 (no)
NZ (1) NZ337386A (no)
PL (1) PL196086B1 (no)
PT (4) PT964677E (no)
SI (3) SI2305194T1 (no)
WO (1) WO1998036728A2 (no)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265353A1 (en) * 1995-07-28 2004-12-30 Zars, Inc. Systems and methods for treating panic attacks
US20020114827A1 (en) * 1995-07-28 2002-08-22 Jie Zhang Methods and apparatus for improved administration of analgesics
US20040024006A1 (en) * 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
DE19746191C2 (de) * 1997-10-18 2000-05-18 Lohmann Therapie Syst Lts Verfahren zur Anwendung eines Wirkstoff enthaltenden Pflasters zur Bekämpfung oder Linderung einer Sucht
CA2314893C (en) 1997-12-22 2005-09-13 Euro-Celtique, S.A. Opioid agonist/antagonist combinations
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
SE9803240D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
BR0108379A (pt) 2000-02-08 2002-11-05 Euro Celtique Sa Composições de liberação controlada contendo agonista e antagonista opióide, método para a preparação de uma formulação em dosagem de analgésico opióide de liberação controlada com potência analgésica aumentada e sistema de administração através da derme para um analgésico opióide
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
DK1255547T3 (da) * 2000-02-08 2008-12-01 Euro Celtique Sa Kontrolleret-frigivelsessammensætninger indeholdende opioid-agonist og antagonist
WO2001064149A1 (en) * 2000-02-29 2001-09-07 Jie Zhang Improved transdermal drug patch
KR100452972B1 (ko) * 2000-05-16 2004-10-14 주식회사 삼양사 경피투여용 하이드로젤 조성물
WO2001093868A1 (fr) * 2000-06-02 2001-12-13 Teijin Limited Bande adhesive contenant de la buprenorphine
GB0021317D0 (en) * 2000-08-30 2000-10-18 Queen Mary & Westfield College Transdermal pharmaceutical delivery composition
ES2309107T3 (es) * 2000-10-23 2008-12-16 Euro-Celtique S.A. Dispositivo y metodos transdermicos para felodipina.
US7018649B2 (en) * 2000-10-23 2006-03-28 Euro-Celtique, S.A. Felodipine transdermal device and methods
EP1335689B1 (en) 2000-10-23 2010-03-17 Euro-Celtique S.A. Loratadine transdermal administration system and use thereof
US6682757B1 (en) 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
US20020106407A1 (en) * 2000-12-11 2002-08-08 Dennis Coleman Method and apparatus for treating breakthrough pain
EP1368023B1 (de) * 2001-02-16 2005-12-28 Grünenthal GmbH Verwendung von buprenorphin zur therapie der harninkontinenz
JP2004525960A (ja) * 2001-02-16 2004-08-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 尿失禁、特に切迫尿失禁の治療用経皮デリバリーディバイスの製造にブプレノルフィンを使用する方法
EP1368356A2 (en) * 2001-03-02 2003-12-10 Euro-Celtique S.A. N-but-3-enyl norbuprenorphine and its use as analgesic
DE60238756D1 (de) 2001-05-11 2011-02-10 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
US7968119B2 (en) * 2001-06-26 2011-06-28 Farrell John J Tamper-proof narcotic delivery system
AU2002316738B2 (en) 2001-07-18 2009-01-08 Euro-Celtique S.A. Pharmaceutical combinations of oxycodone and naloxone
WO2003013433A2 (en) 2001-08-06 2003-02-20 Euro-Celtique S.A. Sequestered antagonist formulations
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
HUP0401191A3 (en) 2001-08-06 2006-11-28 Euro Celtique Sa Opioid agonist formulations with releasable and sequestered antagonist and process for their preparation
WO2003014247A1 (en) * 2001-08-10 2003-02-20 Cosmed. Co., Ltd. Pressure-sensitive adhesive for the skin and tapes or sheets for the skin made by using the same
AU2002361709A1 (en) * 2001-12-17 2003-06-30 Aryx Therapeutics Analgesic delivery systems and methods of use
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
AU2003224742A1 (en) * 2002-03-20 2003-10-08 Euro-Celtique S.A. Method of administering buprenorphine to treat depression
EP1492506B2 (en) 2002-04-05 2016-06-29 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
US20050106249A1 (en) * 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
PT2561860T (pt) * 2002-05-31 2018-05-08 Titan Pharmaceuticals Inc Dispositivo polimérico implantável para a libertação prolongada de buprenorfina
KR20110120358A (ko) 2002-06-10 2011-11-03 유로-셀티크 소시에떼 아노뉨 경피 전달 장치에 포함된 활성 성분의 오용을 방지하는 경피 전달 장치의 처리 시스템
DK1526848T3 (da) * 2002-08-09 2007-10-22 Gruenenthal Gmbh Opiod-receptorantagonister i transdermale systemer med buprenorphin
DE60326354D1 (de) * 2002-08-20 2009-04-09 Euro Celtique Sa Transdermale dosierungsform enthaltend einen wirkstoff und einen antagonisten in freier base und in salz form
SI1551372T1 (en) 2002-09-20 2018-08-31 Alpharma Pharmaceuticals Llc SUBVENCATION DATA AND RELATED CONSTRUCTIONS AND PROCEDURES
EP1545468A4 (en) * 2002-09-20 2007-06-20 Alpharma Inc SUSTAINED RELEASE OPIOID PREPARATIONS AND METHODS OF USE
ATE444296T1 (de) * 2002-10-25 2009-10-15 Euro Celtique Sa Analoga und prodrugs von buprenorphin
NZ539936A (en) * 2002-12-13 2007-06-29 Euro Celtique Sa Transdermal buprenorphine dosage regimen for analgesia
EP1913938A1 (en) 2002-12-13 2008-04-23 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for analgesia
AU2003297074A1 (en) * 2002-12-13 2004-07-09 Euro-Celtique S.A. Transdermal buprenorphine to treat pain in sickle cell crisis
ES2359977T3 (es) 2003-03-31 2011-05-30 Titan Pharmaceuticals, Inc. Dispositivo polimérico implantable para liberación sostenida de agonista de dopamina.
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
US7879357B2 (en) * 2003-04-28 2011-02-01 Bayer Schering Pharma Ag Pharmaceutical composition in the form of a hydrogel for transdermal administration of active ingredients
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
MY141815A (en) 2003-04-30 2010-06-30 Purdue Pharma Lp Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer
WO2004103317A2 (en) * 2003-05-15 2004-12-02 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for treatment of diarrhea
PT1646328E (pt) 2003-07-25 2007-10-24 Euro Celtique Sa Tratamento da abstinência de dependência.
CA2529983C (en) * 2003-07-25 2010-07-20 Bruce E. Reidenberg Preoperative treatment of post operative pain
US20080020028A1 (en) * 2003-08-20 2008-01-24 Euro-Celtique S.A. Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
LT2351555T (lt) 2004-02-23 2016-12-27 Euro-Celtique S.A. Piktnaudžiavimui atspari priemonė, skirta transderminiam opoido įvedimui
US7220842B2 (en) * 2004-04-05 2007-05-22 Dade Behring Inc. Immunoassays for buprenorphine and norbuprenorphine
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
PT1765292T (pt) 2004-06-12 2017-12-29 Collegium Pharmaceutical Inc Formulações de fármacos dissuasoras de abuso
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US20060281775A1 (en) * 2005-06-14 2006-12-14 Applied Pharmacy Services, Inc. Two-component pharmaceutical composition for the treatment of pain
EP1743638A1 (en) 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Pharmaceutical formulations of substituted pyrazoline compounds
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US9066847B2 (en) 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US8357114B2 (en) 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8252329B2 (en) * 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8252328B2 (en) * 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US9289583B2 (en) * 2006-01-06 2016-03-22 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
CA2650412C (en) * 2006-04-13 2016-09-27 Nupathe, Inc. Transdermal methods and systems for the delivery of anti-migraine compounds
DK2526932T3 (en) 2006-06-19 2017-07-17 Alpharma Pharmaceuticals Llc Pharmaceutical composition
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
DE102006054731B4 (de) * 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
DE102006054732B4 (de) * 2006-11-21 2010-12-30 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit Ionenpaar-Mikroreservoiren
JPWO2008120562A1 (ja) * 2007-04-02 2010-07-15 東洋紡績株式会社 帯状疱疹後神経痛治療用錠剤および帯状疱疹後神経痛の治療方法
CA2704929C (en) * 2007-08-07 2018-05-15 Pamela Palmer Compositions and methods for procedural sedation and analgesia using oral transmucosal dosage forms
US20090082383A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched buprenorphine
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
EP2262367A4 (en) * 2008-03-08 2011-04-20 Theraquest Biosciences Inc PHARMACEUTICAL ORAL COMPOSITIONS OF BUPRENORPHINE AND METHOD FOR THEIR USE
CA2728912C (en) * 2008-06-23 2018-04-10 Biodelivery Sciences International, Inc. Multidirectional mucosal delivery devices and methods of use
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
MX347106B (es) 2009-03-10 2017-04-12 Euro-Celtique S A * Coposiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona.
WO2010107761A1 (en) 2009-03-18 2010-09-23 Acelrx Pharmaceuticals, Inc. Improved storage and dispensing devices for administration of oral transmucosal dosage forms
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US20110037455A1 (en) * 2009-08-17 2011-02-17 Oren Navot System for measuring electrical power
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
AU2011295694B2 (en) * 2010-09-03 2015-02-05 Zoetis Belgium S.A. High dose buprenorphine compositions and use as analgesic
WO2012048455A1 (zh) * 2010-10-12 2012-04-19 武汉大学 一种抗病毒透皮吸收贴片及其制备方法
ES2528650T3 (es) * 2010-11-17 2015-02-11 Hexal Ag Sistema terapéutico transdérmico que comprende buprenorfina
DE102011076653A1 (de) 2011-05-27 2012-11-29 Acino Ag Transdermales therapeutisches System enthaltend Buprenorphin und eine alpha-Hydroxysäure
US10813925B2 (en) 2011-09-19 2020-10-27 Carmel—Haifa University Economic Corporation Ltd. Buprenorphine for the treatment of acute suicidality
MX352795B (es) * 2011-12-12 2017-12-07 Lts Lohmann Therapie Systeme Ag Sistema de administracion transdermica que comprende buprenorfina.
EP2793870A4 (en) * 2011-12-21 2016-02-17 Biodelivery Sciences Int Inc DEVICES FOR TRANSMUCOSAL ACTIVE INGREDIENT RELEASE FOR USE IN THE TREATMENT OF CHRONIC PAIN
EP2809307B1 (en) * 2012-01-31 2017-12-20 Grünenthal GmbH Pharmaceutical patch for transdermal administration of (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4-b]indol]-4-amine
SG11201406025UA (en) 2012-04-17 2014-11-27 Purdue Pharma Lp Systems and methods for treating an opioid-induced adverse pharmacodynamic response
CA2882870C (en) * 2012-08-24 2020-12-15 Integurx Therapeutics, Llc Chemical compositions and methods for enhancing transdermal delivery of therapeutic agents
AU2013205080B2 (en) * 2012-12-12 2016-07-07 Lts Lohmann Therapie-Systeme Ag Transdermal Delivery System
WO2014105480A1 (en) 2012-12-28 2014-07-03 Teikoku Pharma Usa, Inc. Extended buprenorphine transdermal delivery compositions and methods for using the same
GB2529789A (en) * 2013-06-04 2016-03-02 Lohmann Therapie Syst Lts Transdermal Delivery system
CA2918004C (en) 2013-07-23 2018-11-20 Euro-Celtique S.A. A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
DE102014013448A1 (de) 2014-09-16 2016-03-17 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales Therapeutisches System umfassend Buprenorphin
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
NZ732808A (en) 2014-12-23 2021-12-24 Acelrx Pharmaceuticals Inc Systems, devices and methods for dispensing oral transmucosal dosage forms
US9656441B2 (en) 2015-01-08 2017-05-23 Alfred E. Tiefenbacher ( Gmbh & Co. Kg) Transdermal patch
CN107660207B (zh) 2015-03-10 2020-09-29 罗德科技公司 丁丙诺啡乙酸盐及用于制备丁丙诺啡的方法
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
JP2021517572A (ja) * 2018-03-13 2021-07-26 エルテーエス ローマン テラピー−ジステーメ アーゲー シリコーンアクリルハイブリッドポリマーを含む経皮治療システム
WO2021163529A2 (en) * 2020-02-13 2021-08-19 Biodelivery Sciences International, Inc. Methods of treatment with buprenorphine
CZ37580U1 (cs) 2022-03-02 2023-12-21 RECUTECH s.r.o Teplo-vlhkosměnná deska a entalpický výměník

Family Cites Families (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3996934A (en) * 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US4058599A (en) 1973-02-24 1977-11-15 Bayer Aktiengesellschaft Ethyleneimine inactivated organisms
US4262003A (en) * 1975-12-08 1981-04-14 Alza Corporation Method and therapeutic system for administering scopolamine transdermally
US4060084A (en) * 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
US4119713A (en) 1977-02-09 1978-10-10 Sam Carosio Analgesic and anti-inflammatory composition
US4379454A (en) * 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
DE3330750A1 (de) * 1983-08-26 1985-03-14 Chemische Werke Hüls AG, 4370 Marl Verfahren zur erzeugung von acetylen und synthese- oder reduktionsgas aus kohle in einem lichtbogenprozess
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4636539A (en) 1984-01-30 1987-01-13 Loctite (Ireland) Limited Instant adhesive composition utilizing calixarene accelerators
US4601893A (en) 1984-02-08 1986-07-22 Pfizer Inc. Laminate device for controlled and prolonged release of substances to an ambient environment and method of use
US4588580B2 (en) * 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
DE3546830C2 (de) 1984-07-23 1995-07-20 Alza Corp Transdermales Abgabesystem zur Verabreichung von Fentanyl
US4626539A (en) 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4834978A (en) 1984-10-01 1989-05-30 Biotek, Inc. Method of transdermal drug delivery
GB8430346D0 (en) * 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US4698062A (en) 1985-10-30 1987-10-06 Alza Corporation Medical device for pulsatile transdermal delivery of biologically active agents
DE3634016A1 (de) * 1986-04-17 1987-10-29 Lohmann Gmbh & Co Kg Flaechenfoermiges therapeutisches system, verfahren zu seiner herstellung und seine verwendung
US4673679A (en) 1986-05-14 1987-06-16 E. I. Du Pont De Nemours And Company Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
USRE33093E (en) 1986-06-16 1989-10-17 Johnson & Johnson Consumer Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
JPS62298530A (ja) 1986-06-16 1987-12-25 Otsuka Pharmaceut Co Ltd 坐薬用医薬組成物
US4938759A (en) 1986-09-02 1990-07-03 Alza Corporation Transdermal delivery device having a rate controlling adhesive
US4908027A (en) * 1986-09-12 1990-03-13 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US5344656A (en) * 1986-09-12 1994-09-06 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US4906463A (en) * 1986-12-22 1990-03-06 Cygnus Research Corporation Transdermal drug-delivery composition
US5091405A (en) * 1987-01-05 1992-02-25 E. I. Du Pont De Nemours And Company Insecticidal pyrazolines
US5171576A (en) 1987-03-09 1992-12-15 Alza Corporation Prevention of contact allergy by coadministration of a corticosteroid with a sensitizing drug
US4879297A (en) * 1987-06-01 1989-11-07 Warner-Lambert Company Fatty acids and their small chain esters as penetration enhancers in aqueous systems
DE3812481A1 (de) * 1987-08-26 1989-03-09 Bayer Ag Wasserhaertende polymerzubereitung
US4915954A (en) 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
US4983395A (en) * 1987-11-12 1991-01-08 Theratech Inc. Device for administering an active agent to the skin or mucosa
US4994278A (en) * 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Breathable backing
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5236714A (en) 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US5026556A (en) * 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
CA2002299A1 (en) * 1988-11-10 1990-05-10 Eugene G. Drust Compositions for the transdermal delivery of buprenorphine salts
US4945103A (en) * 1989-01-17 1990-07-31 Michael Cohen Method of treating pre-menstrual syndrome
US5336210A (en) * 1989-02-28 1994-08-09 Teijin Limited Plaster agent
US5028435A (en) 1989-05-22 1991-07-02 Advanced Polymer Systems, Inc. System and method for transdermal drug delivery
US4956171A (en) * 1989-07-21 1990-09-11 Paco Pharmaceutical Services, Inc. Transdermal drug delivery using a dual permeation enhancer and method of performing the same
US5091186A (en) * 1989-08-15 1992-02-25 Cygnus Therapeutic Systems Biphasic transdermal drug delivery device
US5240711A (en) * 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
DE3939376C1 (no) 1989-11-29 1991-05-08 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De
US5075341A (en) 1989-12-01 1991-12-24 The Mclean Hospital Corporation Treatment for cocaine abuse
EP0432945A1 (en) 1989-12-12 1991-06-19 Warner-Lambert Company A transdermal delivery system for treatment of cocaine and heroin addiction
JP2849937B2 (ja) * 1990-04-18 1999-01-27 日東電工株式会社 医療用貼付剤
CA2062828C (en) * 1990-04-24 1996-04-16 Osafumi Hidaka Pharmaceutical plasters
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
DE4020144A1 (de) * 1990-06-25 1992-01-09 Lohmann Therapie Syst Lts Pflaster mit hohem gehalt an weichmachenden inhaltsstoffen
US5688547A (en) 1990-08-03 1997-11-18 American Cyanamid Company Meal replacement composition and method of weight control
GB9021674D0 (en) * 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
CN1036343C (zh) 1990-11-10 1997-11-05 天津市计划生育研究所 新促黄体生成素释放激素拮抗类似物的制备方法
PL166095B1 (pl) 1991-04-03 1995-03-31 Warszawskie Zaklady Farma Sposób wytwarzania N-cyklopropylometylo-7a -[(S)-1-hydroksy-1,2,2-trimetylopropylo] endo-etano-6,7,8,14-tetrahydronororipaviny
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
WO1992019241A1 (en) 1991-05-07 1992-11-12 Dynagen, Inc. A controlled, sustained release delivery system for smoking cessation
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5225440A (en) * 1991-09-13 1993-07-06 The United States Of America As Represented By The Department Of Health And Human Services Attenuation of the opioid withdrawal syndrome by inhibitors of nitric oxide synthase
US5238933A (en) * 1991-10-28 1993-08-24 Sri International Skin permeation enhancer compositions
US5229130A (en) 1991-12-20 1993-07-20 Cygnus Therapeutics Systems Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5958459A (en) 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5272149A (en) 1992-05-05 1993-12-21 Stalling Reginald W Symptom controlled receptor substitution for addiction withdrawl
WO1993023019A1 (en) 1992-05-11 1993-11-25 Sri International Transdermal drug delivery systems and related compositions and methods of use
AU666735B2 (en) 1992-05-13 1996-02-22 Alza Corporation Transdermal administration of oxybutynin
HU221598B (hu) 1992-06-11 2002-11-28 Theratech Inc. Glicerin alkalmazása bőrön keresztüli hatóanyag-bevitel szabályozására
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US6096756A (en) 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
DE4237453C1 (no) 1992-11-06 1993-08-19 Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
DE4301783C1 (de) * 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
US5512593A (en) 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
ES2164286T3 (es) 1993-04-20 2002-02-16 Hexal Ag Emplasto con sustancias activas.
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
WO1995001167A2 (en) 1993-06-25 1995-01-12 Alza Corporation Incorporating poly-n-vinyl amide in a transdermal system
WO1995005138A1 (en) 1993-08-16 1995-02-23 Cygnus Therapeutic Systems Contact adhesive extends wear time on skin
US5662933A (en) 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
BR9506557A (pt) 1994-01-20 1997-10-28 Akzo Nobel Nv Composição farmacêutica e processo para induzir o crescimento e maturação folicular em individuos do sexo feminino
JPH07206710A (ja) * 1994-01-21 1995-08-08 Nitto Denko Corp 経皮投薬用テープ製剤
PE44995A1 (es) 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
JP2819236B2 (ja) * 1994-05-06 1998-10-30 日東電工株式会社 経皮吸収製剤
US5635203A (en) * 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
US20020006438A1 (en) 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5468457A (en) 1994-12-22 1995-11-21 Osram Sylvania Inc. Method of making tungsten-copper composite oxides
DE4446600A1 (de) * 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen
US6024974A (en) * 1995-01-06 2000-02-15 Noven Pharmaceuticals, Inc. Composition and methods for transdermal delivery of acid labile drugs
US5601839A (en) 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
US5785991A (en) * 1995-06-07 1998-07-28 Alza Corporation Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
WO1997004835A1 (de) 1995-07-28 1997-02-13 Novartis Ag Transdermales system
CA2182851A1 (en) * 1995-08-15 1997-02-16 August Masaru Watanabe Method for treating substance abuse withdrawal
FR2739731B1 (fr) 1995-10-09 1998-01-02 Axon Cable Sa Procede de raccordement de micro-cables coaxiaux aux pistes d'un circuit imprime
DE19642043A1 (de) * 1995-10-23 1997-04-24 Hexal Ag Transdermales therapeutisches System (TTS) für die Verabreichung von Wirkstoffen zur Behandlung von Drogenabhängigkeit oder Drogensucht
US5792740A (en) 1996-03-08 1998-08-11 Firmenich Sa Fragrant macrocyclic lactones
NZ332033A (en) 1996-03-25 1999-09-29 Lohmann Therapie Syst Lts Transdermal therapeutic system (tts) with small application-area thickness and great flexibility, and production process
US6004969A (en) 1996-04-15 1999-12-21 National Science Council Transdermal delivery of buprenorphine preparations
US6271240B1 (en) 1996-05-06 2001-08-07 David Lew Simon Methods for improved regulation of endogenous dopamine in prolonged treatment of opioid addicted individuals
SE9602442D0 (sv) 1996-06-20 1996-06-20 Astra Ab Administration of pharmaceuticals
JPH1036265A (ja) * 1996-07-19 1998-02-10 Nitto Denko Corp ブプレノルフィン経皮吸収製剤
US5837289A (en) * 1996-07-23 1998-11-17 Grasela; John C. Transdermal delivery of medications using a combination of penetration enhancers
EP0821957A3 (en) 1996-08-01 1998-04-22 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating substance abuse
US20010006677A1 (en) 1996-10-29 2001-07-05 Mcginity James W. Effervescence polymeric film drug delivery system
AT405158B (de) * 1996-12-04 1999-06-25 Steyr Daimler Puch Ag Verfahren zur selbsttätigen steuerung der sperrkupplungen eines allradgetriebenen fahrzeuges und fahrzeug mit knicklenkung und sperrbaren differentialen
US6787149B1 (en) 1996-12-12 2004-09-07 El Khoury And Stein Ltd. Topical application of opioid analgesic drugs such as morphine
DE19652188C2 (de) 1996-12-16 2002-02-14 Lohmann Therapie Syst Lts Flache Arzneizubereitung zur Applikation und Freisetzung von Buprenorphin oder einer pharmakologisch vergleichbaren Substanz in der Mundhöhle und Verfahren zu ihrer Herstellung
BR9807828A (pt) 1997-02-07 2000-03-08 Theratech Inc Composições e método para a suplementação de testosterona em mulheres com sintomas de deficiência de testosterona
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
AU7273898A (en) 1997-04-30 1998-11-24 Human Pheromone Sciences, Inc. Method of fixing fragrances in fragrance composition and other compositions
US5919473A (en) * 1997-05-12 1999-07-06 Elkhoury; George F. Methods and devices for delivering opioid analgesics to wounds via a subdermal implant
US5900420A (en) 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
GB2328443B (en) 1997-08-21 2001-09-05 Reckitt & Colmann Prod Ltd In situ formation of pharmaceutically acceptable polymeric material
US5942530A (en) 1997-08-28 1999-08-24 Eli Lilly And Company Method for treating pain
DE19738855C2 (de) 1997-09-05 2001-01-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit haftklebender Reservoirschicht und unidirektional elastischer Rückschicht
RS49982B (sr) * 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
US7011843B2 (en) 1997-10-01 2006-03-14 Lts Lohmann-Therapie Systeme Ag Method for protecting a human being against health impairment by ingestion of a transdermal therapeutic system
DE19746191C2 (de) * 1997-10-18 2000-05-18 Lohmann Therapie Syst Lts Verfahren zur Anwendung eines Wirkstoff enthaltenden Pflasters zur Bekämpfung oder Linderung einer Sucht
US6210705B1 (en) 1997-12-15 2001-04-03 Noven Pharmaceuticals, Nc. Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
CN1204890C (zh) 1997-12-22 2005-06-08 欧罗赛铁克股份有限公司 防止阿片样物质滥用的方法
WO1999045906A1 (en) 1998-03-09 1999-09-16 Trustees Of Tufts College Treatment of compulsive behaviours in man and animals
DE69913111T2 (de) 1998-03-23 2004-06-03 Elan Corp. Plc Vorrichtung zur arzneimittelverarbreichung
EP1079813B1 (en) 1998-04-29 2005-02-09 Virotex Corporation Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
DE19840758A1 (de) 1998-09-07 2000-03-09 Liedtke Pharmed Gmbh Systemische Therapie von Schmerz- und depressiver Befindlichkeit
KR100383252B1 (ko) 1998-12-17 2003-07-16 주식회사 삼양사 부프레놀핀을함유하는경피투여조성물및이를포함하는패취
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
IT1305303B1 (it) 1999-03-10 2001-05-04 Farmigea Spa Uso dell'olio essenziale di niaouli come promotore per la permeazionetransdermica.
US6210699B1 (en) 1999-04-01 2001-04-03 Watson Pharmaceuticals, Inc. Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity
US6554851B1 (en) 1999-05-07 2003-04-29 Scimed Life Systems, Inc. Methods of sealing an injection site
US6436977B1 (en) * 1999-09-29 2002-08-20 Pfizer Inc. Dosing regimens for lasofoxifene
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
JP4659943B2 (ja) * 2000-02-25 2011-03-30 帝三製薬株式会社 塩酸ブプレノルフィン含有貼付剤
US7067116B1 (en) 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
TR200300776T2 (tr) 2000-08-30 2005-10-21 Unimed Pharmaceuticals, Inc. Erkeklerde cinsel organ sertleşmemesinin tedavi edilmesi ve libidonun arttırılması için yöntem.
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US6682757B1 (en) * 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
EP1368356A2 (en) 2001-03-02 2003-12-10 Euro-Celtique S.A. N-but-3-enyl norbuprenorphine and its use as analgesic
CA2441889A1 (en) 2001-03-23 2002-10-03 Albert Einstein College Of Medicine Of Yeshiva University Methods for increasing analgesic potency and attenuating adverse excitatory effects of bimodally-acting opioid agonists by inhibiting gm1-ganglioside
PT1424973E (pt) * 2001-04-23 2010-06-02 Euro Celtique Sa Sistema de eliminação para uma forma de dosagem transdérmica
SI2316439T1 (sl) 2001-05-01 2015-10-30 Euro-Celtique S.A. Proti zlorabi odporni transdermalni sistemi, ki vsebujejo opioid
PT1390866E (pt) 2001-05-22 2010-04-26 Euro Celtique Sa Recipiente e processo para distribuição de formas de dosagem transdérmicas
KR20040007643A (ko) 2001-06-04 2004-01-24 키네티큐 리미티드 패턴화 방법
US20030104976A1 (en) 2001-07-23 2003-06-05 Gudarz Davar Analgesic methods using endothelin receptor ligands
AU2002348135A1 (en) 2001-10-31 2003-05-12 Recovery Pharmaceuticals, Inc. Methods for the treatment of addiction
AU2003224742A1 (en) 2002-03-20 2003-10-08 Euro-Celtique S.A. Method of administering buprenorphine to treat depression
EP1422230B1 (en) 2002-11-25 2007-12-26 Chi Mei Foundation Medical Center Novel ester derivatives of buprenorphine and their preparation processes, and long acting analgestic pharmaceutical compositions
AU2003297074A1 (en) * 2002-12-13 2004-07-09 Euro-Celtique S.A. Transdermal buprenorphine to treat pain in sickle cell crisis
NZ539936A (en) 2002-12-13 2007-06-29 Euro Celtique Sa Transdermal buprenorphine dosage regimen for analgesia
WO2004103317A2 (en) * 2003-05-15 2004-12-02 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for treatment of diarrhea
PT1646328E (pt) 2003-07-25 2007-10-24 Euro Celtique Sa Tratamento da abstinência de dependência.
CA2529983C (en) 2003-07-25 2010-07-20 Bruce E. Reidenberg Preoperative treatment of post operative pain
AU2004266731A1 (en) 2003-08-21 2005-03-03 Transoral Pharmaceuticals, Inc. Compositions for delivering 5-HT agonists across the oral mucosa and methods of use thereof
AU2006242246A1 (en) 2005-05-03 2006-11-09 Innozen, Inc. Edible film for transmucosal delivery of nutritional supplements
EP1968539A2 (en) 2005-12-13 2008-09-17 Biodelivery Sciences International, Inc. Abuse resistant transmucosal drug delivery device
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
EP2452683A3 (en) 2006-06-26 2012-08-22 Amgen Inc. Methods for treating atherosclerosis
ES2577390T3 (es) 2006-07-21 2016-07-14 Biodelivery Sciences International, Inc. Dispositivos de administración transmucosa con mayor captación
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
HUE038022T4 (hu) 2006-10-02 2023-02-28 Spepharm Ag Nem mukoadhezív filmdózisformák
EP2069794A1 (en) 2006-10-03 2009-06-17 University of Southern California Grp78 as a predictor of responsiveness to therapeutic agents
GB2447016A (en) 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Buprenorphine/naloxone compositions
US20080226702A1 (en) 2007-03-16 2008-09-18 Endo Pharmaceuticals, Inc. Transdermal Delivery Form Disposal Systems and Methods
CA2728912C (en) 2008-06-23 2018-04-10 Biodelivery Sciences International, Inc. Multidirectional mucosal delivery devices and methods of use
ES2528650T3 (es) 2010-11-17 2015-02-11 Hexal Ag Sistema terapéutico transdérmico que comprende buprenorfina

Also Published As

Publication number Publication date
DE69835584D1 (de) 2006-09-28
US20110288112A1 (en) 2011-11-24
AU2008261134A1 (en) 2009-01-15
IL131561A0 (en) 2001-01-28
NO20130298L (no) 1999-10-22
NO20131533L (no) 1999-10-22
KR20000075648A (ko) 2000-12-26
SI2305194T1 (sl) 2012-10-30
US20030091631A1 (en) 2003-05-15
HK1103621A1 (en) 2007-12-28
NZ337386A (en) 2001-06-29
US6344212B2 (en) 2002-02-05
EP1570823A3 (en) 2006-01-18
PT2305194E (pt) 2012-08-14
WO1998036728A2 (en) 1998-08-27
EP1570823A2 (en) 2005-09-07
AU743071B2 (en) 2002-01-17
CN1827107A (zh) 2006-09-06
HUP0002342A2 (hu) 2000-12-28
ES2380023T3 (es) 2012-05-07
US20140073663A1 (en) 2014-03-13
CN1252705A (zh) 2000-05-10
NO20151450A1 (no) 1999-10-22
DK0964677T3 (da) 2006-12-11
US20060216340A1 (en) 2006-09-28
EP2305192A1 (en) 2011-04-06
EP0964677B1 (en) 2006-08-16
HU230374B1 (hu) 2016-03-29
EP2305191A1 (en) 2011-04-06
SI0964677T1 (sl) 2006-12-31
US20130197020A1 (en) 2013-08-01
IL201437A (en) 2010-12-30
ATE336212T1 (de) 2006-09-15
NO334290B1 (no) 2014-01-27
NO333139B1 (no) 2013-03-11
USRE41408E1 (en) 2010-06-29
NO332248B1 (no) 2012-08-06
AU2008261134B2 (en) 2012-08-02
USRE41489E1 (en) 2010-08-10
HU230608B1 (hu) 2017-03-28
PT964677E (pt) 2006-12-29
ES2387752T3 (es) 2012-10-01
NO20120563L (no) 1999-10-22
US5968547A (en) 1999-10-19
US20160220559A1 (en) 2016-08-04
HK1096847A1 (en) 2007-06-15
EP2301493A1 (en) 2011-03-30
DK1731152T3 (da) 2013-07-22
ES2423925T3 (es) 2013-09-25
NO333374B1 (no) 2013-05-13
BR9815439A (pt) 2001-10-16
HUP0002342A3 (en) 2001-04-28
EP1570823B1 (en) 2011-12-28
US20150157625A1 (en) 2015-06-11
CZ299414B6 (cs) 2008-07-16
AU2004218685A1 (en) 2004-11-04
AU2925402A (en) 2002-05-16
PT1570823E (pt) 2012-03-02
US20030198675A1 (en) 2003-10-23
NO322515B1 (no) 2006-10-16
US9642850B2 (en) 2017-05-09
EP2305194B1 (en) 2012-05-09
IL131561A (en) 2010-05-31
EP2305193A1 (en) 2011-04-06
USRE41571E1 (en) 2010-08-24
AU6184198A (en) 1998-09-09
HUP1500370D0 (hu) 2000-12-28
ATE538765T1 (de) 2012-01-15
EP1731152A2 (en) 2006-12-13
NO337094B1 (no) 2016-01-18
NO329838B1 (no) 2011-01-10
NO340067B1 (no) 2017-03-06
NO20064395L (no) 1999-10-22
NO994087D0 (no) 1999-08-24
CA2276170A1 (en) 1998-08-27
DE69835584T2 (de) 2007-08-16
AU774779B2 (en) 2004-07-08
IL207067A (en) 2011-12-29
NO20101190L (no) 1999-10-22
US20170056393A1 (en) 2017-03-02
HK1153377A1 (en) 2012-03-30
NO20074292L (no) 1999-10-22
NO994087L (no) 1999-10-22
AU2004218685B2 (en) 2009-01-22
PL196086B1 (pl) 2007-12-31
US6231886B1 (en) 2001-05-15
DE05011213T1 (de) 2007-09-06
CA2276170C (en) 2007-12-04
KR100703101B1 (ko) 2007-04-06
NO329734B1 (no) 2010-12-13
EP0964677A1 (en) 1999-12-22
PT1731152E (pt) 2013-07-31
US20010002259A1 (en) 2001-05-31
EP2305194A1 (en) 2011-04-06
EP0964677A4 (en) 2002-12-18
WO1998036728A3 (en) 1998-12-10
EP1731152A3 (en) 2007-11-14
SI1570823T1 (sl) 2012-03-30
DK1570823T3 (da) 2012-02-20
CZ2015477A3 (cs) 2015-10-21
CZ300999A3 (cs) 2000-03-15
EP1731152B1 (en) 2013-05-01
DK2305194T3 (da) 2012-08-13
JP2000511936A (ja) 2000-09-12
EP2301494A1 (en) 2011-03-30
NO20111441L (no) 1999-10-22
ATE556682T1 (de) 2012-05-15
NO2016013I1 (no) 2016-07-18
PL335306A1 (en) 2000-04-10
CN1827107B (zh) 2010-05-26
HUP1200599A2 (en) 2000-12-28
ES2271988T3 (es) 2007-04-16

Similar Documents

Publication Publication Date Title
NO2017011I1 (no) Buprenorfin
DK0810856T3 (da) Med bånd forsynet doseringsform af aktivt middel med forlænget frigivelse
ATE324907T1 (de) Verbindung und arzneizusammensetzung zur verabreichung von wirkstoffen
ATE288743T1 (de) Pharmazeutische trägervorrichtung welche zur verabreichung von wirkstoffen an schleimhautoberflächen geeignet ist
HUP9901991A2 (hu) Transzdermális eszköz flurbiprofén átadására
DK0973497T3 (da) Farmaceutisk bæreanordning, egnet til udlevering af farmaceutiske forbindelser til slimhindeoverflade
FI971776A0 (fi) Yhdisteet ja koostumukset aktiivisten aineiden antamiseksi
ATE286725T1 (de) Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe
HU900108D0 (en) Composition of controlled active ingredient delivery, operating by hydrogel
CZ20011581A3 (cs) Systém pro podávání bioaktivní sloučeniny inhalací
IS6344A (is) Lyfjasamsetningar sem leiða til aukinna lyfjastyrkja
RS49599B (sr) Upotreba inhibitora h+, k+-atp-aze i glukokortikoida i farmaceutska formulacija
PL348202A1 (en) Pharmaceutically active composition and dispensing device
SE9403389D0 (sv) Pharmaceutical composition containing derivattves of sex hormones
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.
DE59607949D1 (de) Feste arzneimittelform mit polymerem material verteiltem wirkstoff